FDA-cleared profile

Koios DS for Breast

Koios Medical, Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.

Clinical role
Concurrent machine-learning decision support and image-viewer/structured-report aid; the user selects up to two ROIs from up to two orthogonal views.
Images and patients
Mammography/DBT · Soft-tissue breast lesions.
Key limitation
Keep in mind: Not for post-surgical-excision sites or images with Doppler, elastography, or other overlays; not for primary interpretation of digital mammography; not for mobile devices; decisions must not be based solely on the analysis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Soft-tissue breast lesions. Input: DICOM breast-ultrasound images, typically from small-parts linear-array or dedicated breast ultrasound transducers, with up to two user-selected ROIs representing one lesion.
  • Who uses it?Intended users: Trained interpreting physicians who have completed the prescribed training.
  • What does the software produce?Output: Four BI-RADS-aligned categories (Benign, Probably Benign, Suspicious, Probably Malignant), a continuous graphical confidence indicator, lesion shape and orientation classifications, image adjustment/measurement/documentation tools, and structured-report output.
  • What is its most important limitation?Key limitation: Not for post-surgical-excision sites or images with Doppler, elastography, or other overlays; not for primary interpretation of digital mammography; not for mobile devices; decisions must not be based solely on the analysis.

Clinical takeaway. Clinical role: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.

Evidence takeaway. Evidence from the reviewed source record: FDA clinical reader study: 15 readers evaluated 900 randomized cases in aided and unaided reading periods. The primary endpoint was AUC shift for ultrasound examination plus DS versus ultrasound alone: 0.0370 (95% CI 0.030-0.044). A separate 900-lesion system test reported AUC 88.2%; shape/orientation comparisons are agreement/equivalence endpoints, not sensitivity or specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Concurrent machine-learning decision support and image-viewer/structured-report aid; the user selects up to two ROIs from up to two orthogonal views.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM breast-ultrasound images, typically from small-parts linear-array or dedicated breast ultrasound transducers, with up to two user-selected ROIs representing one lesion.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Four BI-RADS-aligned categories (Benign, Probably Benign, Suspicious, Probably Malignant), a continuous graphical confidence indicator, lesion shape and orientation classifications, image adjustment/measurement/documentation tools, and structured-report output.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Diagnostic breast-ultrasound referral/workup for patients with soft-tissue breast lesions; FDA does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Trained interpreting physicians who have completed the prescribed training.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Not for post-surgical-excision sites or images with Doppler, elastography, or other overlays; not for primary interpretation of digital mammography; not for mobile devices; decisions must not be based solely on the analysis.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA clinical reader study: 15 readers evaluated 900 randomized cases in aided and unaided reading periods. The primary endpoint was AUC shift for ultrasound examination plus DS versus ultrasound alone: 0.0370 (95% CI 0.030-0.044). A separate 900-lesion system test reported AUC 88.2%; shape/orientation comparisons are agreement/equivalence endpoints, not sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA clinical reader study: 15 readers evaluated 900 randomized cases in aided and unaided reading periods. The primary endpoint was AUC shift for ultrasound examination plus DS versus ultrasound alone: 0.0370 (95% CI 0.030-0.044). A separate 900-lesion system test reported AUC 88.2%; shape/orientation comparisons are agreement/equivalence endpoints, not sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K190442. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM breast-ultrasound images, typically from small-parts linear-array or dedicated breast ultrasound transducers, with up to two user-selected ROIs representing one lesion.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K190442: Koios DS for Breast

  2. Routing

    Source context, not route validation: Web application with ROI processing on an IIS Windows server; accepts DICOM-compliant files, returns results to the compatible client, can save a report as a PACS addendum, and can export to third-party reporting software.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K190442: Koios DS for Breast

  3. AI processing

    Source context, not route validation: The exact FDA package describes Koios DS for Breast as an ASP.NET web application deployed to an IIS web server in a Windows environment and accessed through a compatible client; user-selected ROIs are sent to the Koios DS for Breast server for processing. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software device is a web application that is deployed to a Microsoft IIS web server and accessed by a user through a compatible client." … "The Koios DS for Breast software is an ASP.NET web application that is deployed to an IIS Web Server inside a Windows operating system environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K190442: Koios DS for Breast

  4. Returned objects

    Source context, not route validation: Four BI-RADS-aligned categories (Benign, Probably Benign, Suspicious, Probably Malignant), a continuous graphical confidence indicator, lesion shape and orientation classifications, image adjustment/measurement/documentation tools, and structured-report output.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K190442: Koios DS for Breast

  5. Viewer/worklist/report

    Unresolved route: Four BI-RADS-aligned categories (Benign, Probably Benign, Suspicious, Probably Malignant), a continuous graphical confidence indicator, lesion shape and orientation classifications, image adjustment/measurement/documentation tools, and structured-report output.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K190442: Koios DS for Breast

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Koios DS for Breast as an ASP.NET web application deployed to an IIS web server in a Windows environment and accessed through a compatible client; user-selected ROIs are sent to the Koios DS for Breast server for processing. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software device is a web application that is deployed to a Microsoft IIS web server and accessed by a user through a compatible client." … "The Koios DS for Breast software is an ASP.NET web application that is deployed to an IIS Web Server inside a Windows operating system environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Web application with ROI processing on an IIS Windows server; accepts DICOM-compliant files, returns results to the compatible client, can save a report as a PACS addendum, and can export to third-party reporting software.
  • Exact FDA submission
  • Checked 2026-09-09
Training
The 510(k) summary states Koios DS for Breast is designed to assist trained interpreting physicians in analyzing breast ultrasound images, and that when utilized by an interpreting physician who has completed the prescribed training, the device provides information that may be useful in rendering an accurate diagnosis.
  • Exact FDA submission
  • Checked 2026-10-27

The summary states a training requirement for users but does not describe the training program, its content, or its provider.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Koios DS for Breast; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K190442
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Soft-tissue breast lesions.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-07-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
18Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K190442 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K190442: Koios DS for Breast

    U.S. Food and Drug Administration - Published 2019-07-03 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Koios DS for Breast model card (K190442)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: anatomy

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K190442

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K190442 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K254131

BAC

DeepHealth, Inc.

Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2026-05-21
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history